Semler Scientific's Q1 2025 earnings call reveals an aggressive bitcoin acquisition strategy alongside efforts to diversify healthcare offerings ...

Read about the move to scale use of AI across all FDA centers by the end of June and learn more about future plans to expand ...

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

VivoSim's NAMkindTM intestine model is a physical wet lab model of intestine made using cells from human donors. VivoSim is also developing what it believes will be industry-best in silico predictions ...

The goal is to provide executives with an empirical baseline for strategic decisions regarding AI, cutting through the hype ...

The FDA  plans to launch generative AI across all of its centers by June 30. The agency has also appointed its first chief AI ...

The FDA is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, part of a bid to get faster and leaner in evaluating drugs, foods, medical devices and diagnostic ...

U.S. and China to pause most tariffs for 90 days, slash reciprocal rates. Amazon-backed Scale AI sets sights on Saudi ...

VUNO Med®-DeepCARS® (DeepCARS) is an AI-powered medical device designed to monitor the risk of in-hospital cardiac arrest within the next 24 hours. It analyzes patients' vital signs-including blood ...

Looking Ahead The FDA’s full-scale adoption of AI technology represents a leap forward in regulatory oversight. By ...